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Malaria held captive
 
Malaria sporozoites that lack a certain protease get trapped in their cyst-like
breeding ground (the oocyst), as shown by Aly and Matuschewski (page
225). Unable to break free, these captive parasites turn in helpless circles
inside the oocyst and their life cycle halts.
Malaria-causing parasites (
 
Plasmodium
 
species) have a complex life cycle that
includes several distinct stages of intra-
cellular growth in vertebrate and mosquito
hosts. Movement from one stage to the
next requires exit from one host cell and
entry into another. Invasion of target
cells has been shown to require parasite-
encoded proteases that, by poorly defined
mechanisms, allow the bug to penetrate
cell membranes. Parasite exit from target
cells has been even less well-studied.
Aly and Matuschewski now identify
a cysteine protease that is selectively
Malaria sporozoites that lack egress
cysteine protease 1 get trapped 
inside the oocyst (shown) in the 
mosquito midgut.
 
expressed at the late sporozoite stage, just before sporozoite release and entry
into the mosquito salivary glands. Elimination of this protease from the
parasite caused mature sporozoites to become trapped inside the oocyst, a
protective compartment forged from the basal lamina of the mosquito
midgut where the sporozoites divide and grow. There they commenced an
unusual circular motion, the significance of which is not yet understood.
These data suggest that 
 
Plasmodium
 
 egress is an active process that
requires the protease—dubbed egress cysteine protease 1—to actively
break down the oocyst wall, rather than a passive one in which the oocyst
simply ruptures once it is filled to capacity. 
 
Dangerously golden
 
The pathogenic bacterium 
 
Staphylococcus aureus
 
 has a colorful resistance 
mechanism. According to Liu and colleagues on page 209, the gold color of
 
S. aureus
 
 is not just for show; the molecules that give the bug its golden hue 
also help it resist attack by neutrophils.
The characteristic gold color of 
 
S. aureus
 
 sets it apart from its avirulent 
relatives, which are mostly unpigmented. The color reflects the production of 
antioxidant molecules called carotenoids—similar to those originally isolated 
from carrots and touted for their ability to boost the immune system and 
decrease tumor growth in humans. Despite the connection between color 
and virulence of 
 
S. aureus
 
, a functional link had never been investigated.
Liu and colleagues now show that these pigmented molecules can also 
help 
 
S. aureus
 
 resist the hosts’ immune defenses. Carotenoids produced by 
 
S. aureus
 
 defused the reactive oxygen species (ROS) that normally help 
neutrophils kill bacteria. Expression of these pigments rendered the normally 
colorless 
 
Streptococcus pyogenes
 
 golden and more virulent. And 
 
S. aureus
 
 that 
were robbed of the ability to make carotenoids could no longer resist 
neutrophil attack and were less pathogenic in mice.
The protective effect of the carotenoids on the bacteria was a function 
of their antioxidant activity, as wild-type bacteria had no advantage over 
carotenoid-deficient bacteria in mice whose neutrophils lacked the ROS-
producing machinery. The authors suggest that drugs that inhibit carotenoid 
synthesis might be useful for treating 
 
S. aureus
 
 infections, which are often 
resistant to traditional antibiotic treatment. 
 
Pollen power
 
On page 295, Agea and colleagues show that
airway dendritic cells (DCs) help trigger aller-
gic responses by capturing phospholipids from
the surface of pollen grains and presenting
them to lipid-reactive T cells. This is the first
report of human T cells that recognize lipids
derived from an environmental allergen. Thus,
according to senior author Fabrizio Spinozzi,
“the concept of the allergen should be ex-
tended to all pollen membrane structures,” not
just proteins.
T cell responses to allergens have tradition-
ally focused on CD4
 
 
 
 T helper 2 (Th2) cells,
which recognize peptides derived from protein
allergens. Generating Th2 responses, however,
requires the time-consuming processes of
antigen processing and presentation, whereas
allergic T cell responses develop very rapidly.
Spinozzi thus suspected that something faster
was at work.
Spinozzi’s group now shows that phospho-
lipids present on the surface of pollen grains
bind to CD1 molecules on airway DCs, which
then trigger lipid-reactive T cells to proliferate
and produce cytokines. DCs that had been
chemically fixed could still stimulate T cells,
suggesting that the lipids could be captured
directly from the pollen grains and did not
require processing by the DC.
These lipid-specific T cells were most
prevalent during allergy season and were rarely
found in nonallergic individuals. In addition,
greater numbers of CD1-expressing DCs were
found in the airways of allergic individuals,
which may help explain why nonallergic people
don’t respond to pollen-derived lipids in the
same way. 
Airway dendritic cells (red) capture lipids from 
pollen grains (green) and present them on MHC 
CD1 molecules to lipid-reactive T cells.
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Breathing easy with carbon monoxide
 
Ancient Greek philosophers extolled moderation in all things. On page 283, Minamoto and colleagues
show that carbon monoxide (CO) inhalation is no exception. In a mouse model of trachea transplantation, 
inhaled CO—in moderation—prevented the development of lethal obstructive airway disease.
CO gas is both a toxic air pollutant and a normal byproduct of cellular heme metabolism. Although 
CO is well-known for its role as an asphyxiant, recent studies have revealed its virtues, which include 
anti-inflammatory and anti-apoptotic effects on a variety of cell types. CO has also been shown to inhibit 
the rejection of xenogeneic heart transplants in rats.
Minamoto et al. now add to that list of virtues by showing that treating mice with low-dose inhaled 
CO reduced the T cell infiltration and airway obstruction that develops after allogeneic tracheal 
transplantation. The benefits of endogenous CO were evident based on comparisons with mice that 
received grafts lacking the CO-synthesizing enzyme hemoxygenase-1 
(Hmox-1), which developed more severe disease than mice that 
received wild-type grafts.
This group previously showed that the development of post-transplant 
airway obstruction requires the expression of inducible nitric oxide 
synthase (iNOS). They now find that CO counterbalances the production 
of nitric oxide by inhibiting the activation of the transcription factor 
NF-
 
 
 
B, which drives the expression of iNOS.
This came as a surprise to the authors, as most other known effects 
of CO depend on activation of the MAP kinase or cyclic GMP signaling 
pathways. Further experiments are required to determine how CO 
inhibits NF-
 
 
 
B activation. But in the meantime, these data suggest that 
increasing endogenous CO levels might be therapeutic in transplant 
patients who develop a lethal, and currently untreatable, complication 
of lung transplantation called obliterative bronchiolitis. 
Inhaled carbon monoxide reduces T cell (brown) invasion of the 
airways following allogeneic tracheal transplantation.
 
Clotting revisited
 
On page 271, Renné and colleagues show that the absence of
a clot-promoting protein in mice keeps arteries from clog-
ging with no risk of excessive bleeding. These data challenge the
decades-old belief that this protein—called factor XII (FXII)
or Hageman factor—has no impact on clotting in vivo.
Blood clotting depends on the sequential activation of
proteins, called clotting factors, that culminates in the pro-
duction of fibrin—the protein that forms the meshwork of
the clot. This process must be tightly regulated, as too little
clotting can lead to bleeding disorders and too much clotting
can lead to blood vessel blockage, which triggers strokes and
heart attacks.
Deficiencies in some blood clotting proteins, such as tissue
factor and factor VII, result in fatal bleeding disorders. But
deficiencies in FXII are not associated with abnormal bleeding,
and thus this factor has long been considered dispensable for
normal clotting.
Renné and colleagues now reexamine a role for this
clotting factor in FXII-deficient mice. As they had previously
reported (and similar to the situation in humans), these mice
developed no spontaneous bleeding disorders. However, the
FXII-deficient mice were less likely to develop blocked arteries
(thrombosis) in response to induced vessel injury. Thrombosis
formation was initiated normally in the FXII-deficient mice,
but the clots were unstable and detached from the vessel wall
before they could grow large enough to impede blood flow,
suggesting that FXII is required not to initiate, but rather to
propagate, the clotting reaction.
Consistent with these findings, elevated plasma levels of
FXII in humans have been associated with increased coro-
nary artery disease, and lower levels with protection. Thus
the authors suggest that drugs that inhibit FXII might be
useful in treating heart disease without increasing the risk of
spontaneous bleeding. FXII-driven fibrin formation thus
appears to be essential for pathological thrombus formation.
The beneficial effects of this pathway, however, remain
mysterious. 
Vessel-blocking thrombus formation (white) in damaged mesenteric ves-
sels is prevented in the absence of coagulation factor XII (bottom panels).
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